Extended Data Fig. 8: Intermediate signatures are associated with a worse clinical outcome in prostate cancer.
From: ERG-driven prostate cancer initiation is cell-context dependent and requires KMT2A and DOT1L
(a) IM marker gene expression in publicly available human normal and prostate cancer datasets (TCGA 2015; Bolis et al 2021). (Top) n = 173 (normal), 708 (primary PCa). (Bottom) E, ERG-fusion-positive (n = 89); P, PTEN deep deletion (n = 10); EP, ERG-fusion-positive and PTEN deep deletion (n = 40); DN, double negative (ERG fusion-negative, PTEN deep deletion-negative) (n = 151). The center line represents the median, the box limits represent the upper and lower quartiles and the minimum and maximum whiskers represent the 10th and 90th percentiles, respectively. (b) Expression of Ar and Ar pathway genes across scRNA-seq clusters in mice. (c) Progression-free survival outcome using indicated signatures from two independent cohorts of patients with primary PCa, stratified based on ERG status (see also in Fig. 5c). Data represent mean ± s.d.; ns, not significant; unpaired two-tailed t-test (a, top); one-way ANOVA with Tukey posttest (a, bottom); Log-rank (Mantel-Cox) test (c).
